Recurrence risk score based on the specific activity of CDK1 and CDK2 predicts response to neoadjuvant paclitaxel followed by 5-fluorouracil, epirubicin and cyclophosphamide in breast cancers
Titel:
Recurrence risk score based on the specific activity of CDK1 and CDK2 predicts response to neoadjuvant paclitaxel followed by 5-fluorouracil, epirubicin and cyclophosphamide in breast cancers
Auteur:
Kim, S.J. Nakayama, S. Shimazu, K. Tamaki, Y. Akazawa, K. Tsukamoto, F. Torikoshi, Y. Matsushima, T. Shibayama, M. Ishihara, H. Noguchi, S.